Effect of hypoxia inducible factor-1 antisense oligonucleotide on liver cancer

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 8, 2015, Pages 12650-12655

  Li, Hongzhang ^a   Chen, Jiaoe ^a   Zen, Wanli ^a   Xu, Xuehua ^a   Xu, Yanjun ^a   Chen, Qiang ^a   Yang, Tiangan ^a  

^a Sanmen People's Hospital   (China)

Author keywords

Antisense oligonucleotide; Hepatocellular carcinoma; Hypoxia inducible factor 1

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CFU COUNTING; CONTROLLED STUDY; GENE TRANSFER; GENETIC TRANSFECTION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PLASMID; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR RESISTANCE; WESTERN BLOTTING;

EID: 84943303151     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Befeler AS and Di Bisceglie AM. Hepato-cellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122: 1609-1619.
2. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11: 790-800.
3. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxo-rubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-1538.
4. Hopfl G, Wenger RH, Ziegler U, Stallmach T, Gardelle O, Achermann R, Wergin M, Kaser-Hotz B, Saunders HM, Williams KJ, Stratford IJ, Gassmann M, Desbaillets I. Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res 2002; 62: 2962-2970.
5. Bussink J, Kaanders JH and van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003; 67: 3-15.
6. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-943.
7. Fedele AO, Whitelaw ML and Peet DJ. Regulation of gene expression by the hypoxia-inducible factors. Mol Interv 2002; 2: 229-243.
8. Semenza GL. Life with oxygen. Science 2007; 318: 62-64.
9. Fulda S and Debatin KM. HIF-1-regulated glucose metabolism: a key to apoptosis resistance? Cell Cycle 2007; 6: 790-792.
10. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464-468.
11. Hockel M and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-276.
12. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, Wenger RH. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003; 22: 3213-3220.
13. Scomparin A, Polyak D, Krivitsky A, Satchi-Fainaro R. Achieving successful delivery of oligonucleotides-From physico-chemical characterization to in vivo evaluation. Biotechnol Adv 2015; Epub ahead of print].
14. Castanotto D and Stein CA. Antisense oligonucleotides in cancer. Curr Opin Oncol 2014; 26: 584-589.
15. Hu F, Deng X, Yang X, Jin H, Gu D, Lv X, Wang C, Zhang Y, Huo X, Shen Q, Luo Q, Zhao F, Ge T, Zhao F, Chu W, Shu H, Yao M, Fan J, Qin W. Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1α to promote the metastasis of hepatocellular carcinoma. Oncogene 2015; Epub ahead of print].
16. Ho TK, Rajkumar V, Ponticos M, Leoni P, Black DC, Abraham DJ, Baker DM. Increased endogenous angiogenic response and hypoxia-inducible factor-1alpha in human critical limb ischemia. J Vasc Surg 2006; 43: 125-133.
17. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 2006; 66: 632-637.